Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2018, which is set as follows: March 8, 2018: Publication of 2017 financial statements...

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...

Lirilumab continues to be well-tolerated in monotherapy and in combination across multiple tumor indications in an exploratory clinical program with partner Bristol-Myers Squibb The combination of...

Cash, cash equivalents and financial assets amounting to €195.7 million Robust cash position allows for further investment in portfolio of proprietary immuno-oncology programs Innate Pharma continues...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that final results of the dose-escalation part of the ongoing Phase I study investigating IPH4102 in patients with...

Cash, cash equivalents and financial assets* for the Company amounted to €204.1m (million euros) as of June 30, 2017 Significant clinical progress within the period: Dose-escalation data of the...

IPH5401, an anti-C5aR antibody, potentially reverses tumor immuno-suppressive microenvironment and overcomes tumor resistance; preclinical data suggest that combined C5aR and PD-1 blockade...

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...

The acquisition of the anti-C5aR, a first-in-class clinical-stage antibody, announced on June 2, 2017, is now finalized; The 3,343,748 new ordinary shares have been issued to Novo Nordisk A/S at a...

All proposed resolutions were voted according to management’s recommendations; Bpifrance Participations, represented by Maïlys Ferrere, and Pr. Jean-Charles Soria were appointed to the Supervisory...